Sustiva

Country: European Union

Language: Polish

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

efawirenz

Available from:

Bristol-Myers Squibb Pharma EEIG

ATC code:

J05AG03

INN (International Name):

efavirenz

Therapeutic group:

Środki przeciwwirusowe do użytku ogólnoustrojowego

Therapeutic area:

Infekcje HIV

Therapeutic indications:

Sustiva jest wskazany w leczeniu przeciwwirusowym połączenie człowieka-niedoboru odporności Wirus-1 (HIV-1)-zakażonych osób dorosłych, młodzieży i dzieci trzech lat życia i starsze. Стокрин nie zostały odpowiednio zbadane w pacjentach z zaawansowanym stadium zakażenia HIV, a mianowicie u pacjentów z poziomem CD4 < 50 komórek/mm3, lub po niepowodzeniu proteazy-inhibitor (PI)-zawierający schematów. Chociaż oporności krzyżowej èfavirenza z IP nie został zarejestrowany, w chwili obecnej nie ma wystarczających danych na temat skuteczności późniejszego wykorzystania PI na podstawie połączenie terapii nieskuteczność schematów zawierających Сустива.

Product summary:

Revision: 48

Authorization status:

Upoważniony

Authorization date:

1999-05-28

Patient Information leaflet

                                1/1
NUMER EU
NAZWA
WŁASNA
MOC
POSTAĆ
FARMACEUTYCZNA
DROGA PODANIA
RODZAJ OPAKOWANIA
WIELKOŚĆ OPAKOWANIA
EU/1/99/110/001
Sustiva
50 mg
Kapsułka twarda
Doustnie
butelka (HDPE)
30 kapsułek
EU/1/99/110/002
Sustiva
100 mg
Kapsułka twarda
Doustnie
butelka (HDPE)
30 kapsułek
EU/1/99/110/003
Sustiva
200 mg
Kapsułka twarda
Doustnie
butelka (HDPE)
90 kapsułek
EU/1/99/110/004
Sustiva
200 mg
Kapsułka twarda
Doustnie
blister (alu/PVC)
42 kapsułki
EU/1/99/110/008
Sustiva
600 mg
Tabletka powlekana
Doustnie
butelka (HDPE)
30 tabletek
EU/1/99/110/009
Sustiva
600 mg
Tabletka powlekana
Doustnie
blister (alu)
30 tabletek
EU/1/99/110/010
Sustiva
600 mg
Tabletka powlekana
Doustnie
blister (alu)
90 tabletek
Produkt leczniczy bez ważnego pozwolenia na dopuszczenie do obrotu
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1/1
NUMER EU
NAZWA
WŁASNA
MOC
POSTAĆ
FARMACEUTYCZNA
DROGA PODANIA
RODZAJ OPAKOWANIA
WIELKOŚĆ OPAKOWANIA
EU/1/99/110/001
Sustiva
50 mg
Kapsułka twarda
Doustnie
butelka (HDPE)
30 kapsułek
EU/1/99/110/002
Sustiva
100 mg
Kapsułka twarda
Doustnie
butelka (HDPE)
30 kapsułek
EU/1/99/110/003
Sustiva
200 mg
Kapsułka twarda
Doustnie
butelka (HDPE)
90 kapsułek
EU/1/99/110/004
Sustiva
200 mg
Kapsułka twarda
Doustnie
blister (alu/PVC)
42 kapsułki
EU/1/99/110/008
Sustiva
600 mg
Tabletka powlekana
Doustnie
butelka (HDPE)
30 tabletek
EU/1/99/110/009
Sustiva
600 mg
Tabletka powlekana
Doustnie
blister (alu)
30 tabletek
EU/1/99/110/010
Sustiva
600 mg
Tabletka powlekana
Doustnie
blister (alu)
90 tabletek
Produkt leczniczy bez ważnego pozwolenia na dopuszczenie do obrotu
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-03-2024
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 14-03-2024
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 14-03-2024
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 14-03-2024
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 14-03-2024
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 14-03-2024
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 14-03-2024
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 14-03-2024
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 14-03-2024
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 14-03-2024
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 14-03-2024
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-03-2024
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 14-03-2024
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 14-03-2024
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 14-03-2024
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 14-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 14-03-2024
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 14-03-2024
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 14-03-2024
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 14-03-2024
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 14-03-2024
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 14-03-2024
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 14-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 14-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 14-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 14-03-2024
Patient Information leaflet Patient Information leaflet Croatian 14-03-2024
Public Assessment Report Public Assessment Report Croatian 26-01-2018

Search alerts related to this product

View documents history